Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
Several ongoing trials are evaluating incretin-based therapies, including GLP-1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in people with type 2 diabetes and obesity.
Authors
- Jae Hyun Bae (ORCID: https://orcid.org/0000-0002-1384-6123)
- Young Min Cho (ORCID: https://orcid.org/0000-0002-2331-6126)
Institutions
- Seoul National University (KR)
- Seoul National University Hospital (KR)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1111/jdi.14336
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77